# US 2001/0034445 A1 · Vitronectin receptor antagonists

> Agents: this data is available as JSON from the patentgrep API and MCP server — see https://patentgrep.com/llms.txt

- Number: US 2001/0034445 A1
- Document ID: US20010034445A1
- Status: Published application
- Kind: A1
- Application number: 09/769,125
- Filed: 2001-01-24
- Published: 2001-10-25
- Earliest claimed: 1995-12-29
- Assignees: SmithKline Beecham Corporation
- Inventors: Fadia E. Ali; William E. Bondinell; Richard M. Keenan; Thomas Wen-Fu Ku; William H. Miller; James Samanen
- Web page: https://patentgrep.com/patent/US20010034445A1

## CPC

- C07D 213/73: Unsubstituted amino or imino radicals
- C07D 401/04: directly linked by a ring-member-to-ring-member bond
- C07D 401/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 401/10: linked by a carbon chain containing aromatic rings
- C07D 401/12: linked by a chain containing hetero atoms as chain links
- C07D 405/12: linked by a chain containing hetero atoms as chain links
- C07D 413/06: linked by a carbon chain containing only aliphatic carbon atoms
- C07D 487/04: Ortho-condensed systems
- C07D: HETEROCYCLIC COMPOUNDS (macromolecular compounds C08)

## Abstract

Compounds of formula (I) are disclosed which are vitronectin receptor antagonists useful in the treatment of osteoporosis. 1

## Claims

### Claim 1

A compound according to formula (I):
58
wherein
A is a fibrinogen antagonist template;
W is a linking moiety of the form —(CHRg)a—U—(CHRg)b—V—;
Q1, Q2 and Q3 are independently N or C—Ry, provided that no more than one of Q1, Q2 and Q3 is N;
R′ is is H or C1-6alkyl, C3-7cycloalkyl-C0-6alkyl or Ar—C0-6alkyl
R″ is R′, —C(O)R′ or —C(O)OR′;
Rg is H or C1-6alkyl, Het-C0-6alkyl, C3-7cycloalkyl-C0-6alkyl or Ar—C0-6alkyl;
Rk is Rg, —C(O)Rg or —C(O)ORg
Ri is H, C1-6alkyl, Het-C0-6alkyl, C3-7cycloalkyl-C0-6alkyl, Ar—C0-6alkyl, Het-C0-6alkyl-U′-C1-6alkyl, C3-7cycloalkyl-C0-6alkyl-U′-C1-6alkyl or Ar—C0-6alkyl-U′-C1-6alkyl;
Ry is H, halo, —ORg, —SRg, —CN, —NRgRk, —NO2, —CF3, CF3S(O)r—, —CO2Rg, —CORg or —CONRg2;
U and V are absent or CO, CRg2, C(═CRg2), S(O)c, O, NRg, CRgORg, CRg(ORk)CRg2, CRg2CRg(ORk), C(O)CRg2, CRg2C(O), CONRi, NRiCO, OC(O), C(O)O, C(S)O, OC(S), C(S)NRg, NRgC(S), S(O)2NRg, NRgS(O)2 N═N, NRgNRg, NRgCRg2, NRgCRg2, CRg2O, OCRg2, CRg═CRg, C≡C, Ar or Het;
a is 0, 1 or 2;
b is 0, 1 or 2;
c is 0, 1 or 2;
r is 0, 1 or 2;
u is 0 or 1; and
v is 0 or ;
or pharmaceutically acceptable salts thereof;
provided that:
(i) when v is 0, and R′, R″ and Ry are H, and Q1-Q3 are CH, W-A is not 7-aminocarbonyl-2,3,4,5-tetrahydro-3-oxo-4-methyl-1H-1,4-benzodiazepine-2-acetic acid, 7-aminocarbonyl-1-acetyl-2,3,4,5-tetrahydro-3-oxo-4-methyl-1H-1,4-benzodiazepine-2-acetic acid, or 7-aminocarbonyl-2,3,4,5-tetrahydro-3-oxo-4-methyl-1H-1-benzazepine-2-acetic acid, or the methyl esters thereof;
(ii) when v is 0 or 1 and R′, R″ and Ry are H, and Q1-Q3 are CH, W-A is not 3-propanoyl-glycyl-aspartyl-phenylalanine, or
59
and the benzyl esters thereof.

### Claim 2 (depends on 1)

A compound according to claim 1 in which Q1, Q2 and Q3 are each CH, and u is 0.

### Claim 3 (depends on 1)

A compound according to claim 1 in which R′ is H and R″ is H or C1-4alkyl.

### Claim 4 (depends on 1)

A compound according to claim 1 in which W is —(CHRg)a—CONRi— or —(CHRg)a—NRiCO—.

### Claim 5

A compound according to formula (I) in which A is chosen from the group of
60
and which has 13-14 covalent bonds between the acidic moiety and the first nitrogen in the pyridine ring.

### Claim 6 (depends on 1)

A compound according to claim 1 in which is:
61
wherein
A1-A2 is NR1—CH, NC(O)R3—CH, N═C, CR1═C, CHR1—CH, O—CH or S—CH;
R1 is H, C1-6 alkyl or benzyl;
R2 is (CH2)qCO2H;
R4 is H, C1-6alkyl, Ar—C0-6alkyl, Het-C0-6alkyl, or C3-6cycloalkyl-C0-6alkyl; and
q is 1, 2 or 3.

### Claim 7 (depends on 6)

A compound according to claim 6 wherein A1-A2 is NH—CH and R2 is CH2CO2H.

### Claim 8 (depends on 7)

A compound according to claim 7 wherein W is —(CHRg)a—CONRi— or —(CHRg)a—NRiCO—.

### Claim 9 (depends on 1)

A compound according to claim 1 which is:
3-[3,4-Dihydro-8-[[[(6-amino2-pyridinyl)methyl]methylamino]carbonyl]-1-methyl-2,5-dioxo-1H-1,4-benzodiazepine]4-propanoic acid;
3-[4H-imidazo[1,2-a][1,4]benzodiazepine-5(6H)-1-methyl-6oxo-9-[[[(6-amino-2-pyridinyl) methyl]methylamino]carbonyl]-5-propanoic acid;
4-[4-[2-(6-Amino-2-pyridinyl)ethyl]-1-piperazinyl]-1-piperidineacetic acid;
1-Hydroxyl-4-[4-[(6-amino-2-pyridinyl)methyl]-1-piperazinyl]-cyclohexaneacetic acid;
1-Hydroxyl-4-[4-[2-(6-amino-2-pyridinyl)ethyl]-1-piperazinyl]-cyclohexaneacetic acid;
4-[4-[(6-Amino-2-pyridinyl)methyl]-1-piperazinyl]-1-piperidineacetic acid;
N-[[1-[[2-(6-Amino-2-pyridinyl)ethyl]carbonyl]-3-piperidinyl]carbonyl]-b-alanine;
2-[(6-Amino-2-pyridinyl)methyl]-5-[2-(carboxy-ethyl)amino]carbonyl]; -2,3-dihydro-3-oxo-1H-isoindole;
(S)-2-(Butylsulfonylamino)-3-[4-[[3-(6-amino-2-pyridinyl)propyl]oxy]phenyl]propionic acid;
N-[3(R)-[2-(6-Amino-2-pyridinyl)ethyl]-2-oxopiperidinyl]acetyl]-3(R)-methyl-b-alanine;
3-[[[3-[2-(6-Aminopyrid-2-yl)ethyl]isoxazolin-5(R,S)-yl]acetyl]amino]-3(R,S)-methylpropanoic acid;
N-[3-[[[(6-Amino-2-pyridinyl)methyl]carbonyl]amino]benzoyl]-b-alanine;
[[1-[N-[[(6-Amino-2-pyridinyl))methyl]carbonyl]tyrosyl]-4-piperidinyl]oxy]acetic acid;
(±)-3-[[[[2-(6-Aminopyrid-2-yl)ethyl]amino]succinoyl]amino]-4-pentynoic acid;
(S)-4-[[[(6-Amino-2-pyridinyl)methyl]carbonyl]glycyl]-3-methoxycarbonylmethyl-2-oxopiperazine-1-acetic acid;
(3S,5S)-5-[4-[(6-Amino-2-pyridinyl)methyl]phenyl]oxymethyl]-3-carboxymethyl-2-pyrrolidinone;
1-[(6-Amino-2-pyridinyl)methyl]-3-[4-(2-carboxyethyl)phenyl]-4-methoxy-3-pyrrolin-2-one;
4-[[[(6-Amino-2-pyridinyl)methyl]methylamino]acetyl]phenoxyacetic acid;
2,2′-[[4-[[[(6-Amino-2-pyridinyl)methyl]methylamino]acetyl]-1,2-phenylene]bis(oxy)]bis-acetic acid;
4-[[[[(6-Amino-2-pyridinyl)methyl]carbonyl]methylamino]acetyl]phenoxyacetate;
4-[[[[(6-Amino-2-pyridinyl)methyl]carbonyl]methylamino]acetyl]-1,2-phenylenedioxydiacetic acid;
1-[(2-Amino-6-pyridinyl)methyl]-3-(4[2-(carboxy)ethyl)]phenyl]-3-oxo-imidazolidine;
[6-[[[(6-Amino-2-pyridinyl)methyl]methylamino]carbonyl]-1,2,3,4-tetrahydroisoquinolin-2-yl]acetic acid;
[6-[[[(6-Amino-2-pyridinyl)methyl]methylamino]carbonyl]-1,2,3,4-tetrahydro-1-oxo-isoquinolin-2-yl]acetic acid;
[6-[[[[(6-Amino-2-pyridinyl)methyl]carbonyl]amino]tetralin-2-yl]acetic acid;
[6-[[[[(6-Amino-2-pyridinyl)methyl]methylamino]carbonyl]tetralin-2-yl)acetic acid;
[5-[[[[(6-Amino-2-pyridinyl)methyl]carbonyl]amino]benzofuran-2-yl]propionic acid;
[5-[[[[(6-Amino-2-pyridinyl)methyl]carbonyl]amino]-2,3-dihydro-benzofuran-2-yl]propionic acid;
[5-[[[[(6-Amino-2-pyridinyl)methyl]methylamino]carbonyl]benzofuran-2-yl]propionic acid;
[5-[[[[(6-Amino-2-pyridinyl)methyl]methylamino]carbonyl]-2,3-dihydro-benzofuran-2-yl]-propionic acid; or
(±)-3-[[[4-(6-Amino-2-pyridinyl)butanoyl]glycyl]amino]-4-pentynoic acid.

### Claim 10 (depends on 1)

A compound according to claim 1 which is:
(S)-7-[[[(6-Amino-2-pyridinyl)methyl]methylamino]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic;
(S)-7-[[[(6-Amino-2-pyridinyl)methyl]amino]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid;
(S)-7-[[[(6-Ethylamino-2-pyridinyl)methyl]amino]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid; or
(±)-7-[[[(2-Amino-4-pyrimidinyl)methyl]methylamino]carbonyl]-2,3,4,5-tetrahydro-4-methyl-3-oxo-1H-1,4-benzodiazepine-2-acetic acid.

### Claim 11 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

A pharmaceutical composition which comprises a compound according to any one of claims 1-10 and a pharmaceutically acceptable carrier.

### Claim 12 (depends on 1)

A method of treating a disease state in which antagonism of the vitronectin receptor is indicated which comprises administering a compound according to claim 1.

### Claim 13 (depends on 12)

A method according to claim 12 for inhibiting angiogenesis or treating atherosclerosis, restenosis, inflammation, cancer or osteoporosis.

### Claim 14 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The use of a compound according to any one of claims 1-10 in the manufacture of a medicament.

### Claim 15 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The use of a compound according to any one of claims 1-10 in the manufacture of a medicament for the inhibition of the vitronectin receptor in a mammal in need thereof.

### Claim 16 (depends on 1, 2, 3, 4, 5, 6, 7, 8, 9, 10)

The use of a compound according to any one of claims 1-10 in the manufacture of a medicament for the treatment of atherosclerosis, restenosis, inflammation, cancer or osteoporosis.

### Claim 17 (depends on 1)

A process for preparing a compound of formula (I) as defined in claim 1, which process comprises reacting a compound of formula (XVI) with a compound of formula (XVII):
62
wherein:
Q1, Q2, Q3, Ry, R′, R″, u, v and A are as defined in formula (I), with any reactive functional groups protected; and
L1 and L2 are groups which react to form a covalent bond in the moiety W as defined in formula (I);
and thereafter removing any protecting groups, and optionally forming a pharmaceutically acceptable salt.
